Bortezomib
Category: Proteasome Inhibitor
Peptide boronic acid FDA-approved for multiple myeloma treatment.
Half-Life: 4 hours
Benefits
- Cancer cell death induction
- Multiple myeloma treatment
- Established efficacy
Side Effects
- Peripheral neuropathy
- Fatigue
- GI effects
- Low blood counts